logo
Nurses threaten industrial action ballot after pay offer rejected

Nurses threaten industrial action ballot after pay offer rejected

Yahooa day ago
The Royal College of Nursing (RCN) has warned its members will be balloted on industrial action if the Government fails to reach an agreement on investment in the profession over the summer.
It comes after members of the union rejected a 3.6% pay increase for 2025/26 in England.
Professor Nicola Ranger, general secretary and chief executive of the RCN, said nurses feel 'deeply undervalued'.
The Department of Health and Social Care (DHSC) said the Government 'hugely' values the work of nurses, but stressed the profession has had 'two above-inflation pay rises'.
The RCN represents hundreds of thousands of nurses across the NHS in England.
According to the union, 91% of members voted to reject the pay award on a 56% turnout, with more than 170,000 staff taking part.
It warned the profession faces widespread vacancies, stunted career progression and years of pay erosion, and it urged ministers to use the summer to agree an investment plan or face a formal escalation to a dispute and a ballot on industrial action.
Prof Ranger said: 'My profession feels deeply undervalued and that is why record numbers are telling the Government to wake up, sense the urgency here and do what's right by them and by patients.
'Record numbers have delivered this verdict on a broken system that holds back nursing pay and careers and hampers the NHS.
'As a safety-critical profession, keeping hold of experienced nursing staff is fundamentally a safety issue and key to the Government's own vision for the NHS.
'Long-overdue reforms to nursing career progression and the NHS pay structure aren't just about fairness and equity but are critical for patient safety.'
Nurses in Wales and Northern Ireland were consulted on the same pay award and voted to reject it, according to the RCN.
Prof Ranger added: 'We deliver the vast majority of care in every service and deserve to be valued for all our skill, knowledge and experience.
'To avoid formal escalation, the Government must be true to its word and negotiate on reforms of the outdated pay structure which traps nursing staff at the same band their entire career.'
A DHSC spokesperson said: 'After receiving two above-inflation pay rises from this Government, new full-time nurses will earn £30,000 in basic pay for the first time this year, so it's disappointing that RCN members are dissatisfied with this year's pay rise.
'We hugely value the work of nurses, and through our 10-Year Health Plan, we are rebuilding the NHS for the benefit of patients and staff, and ensuring nursing remains an attractive career choice.
'This Government is clear we can't move any further on headline pay but will work with the RCN to improve their major concerns, including pay structure reform, concerns on career progression and wider working conditions.'
Nurses staged unprecedented industrial action over pay in 2022 and 2023.
In June 2023, the threat of more strikes ended because a ballot on further walkouts failed to meet the legal threshold of 50%.
An RCN executive director claimed nursing salaries need to be 'raised at the bottom' with clearer career progression opportunities to head off a 'crisis'.
Patricia Marquis told BBC Radio 4's World At One programme: 'Nursing pay has fallen further and further behind after years and years of below-inflation pay rises.
'We could argue about the level of inflation over the last few years, but their salaries are really worth less than they were previously.
'But the issue is bigger than that. The issue we can see is not going to be solved in one year with a simple percentage pay rise.
'We need to see nursing salaries raised at the bottom and the career progression recognised for nurses across all of their experience ranges – so it's not about the percentage pay rise, it's about the crisis in nursing and the solutions that the Government needs to come to the table to discuss to ensure that nursing is a profession that people want to join and that there are enough nurses to provide the care that the patients and the public need.'
Responding to a question on the prospect of industrial action, Ms Marquis said 'if we have to go there, we will have to go there'.
A poll published earlier this week found Britons are split on the idea of nurses striking over pay.
The YouGov survey found 19% of 4,300 British adults 'strongly support' nurses going on strike, while 28% 'somewhat' back them.
Meanwhile 23% said they 'strongly oppose' strike action while one in five (20%) 'somewhat oppose' it.
The RCN warning over a potential ballot for industrial action follows a five-day walkout by resident doctors in England, with medics returning to work at 7am on Wednesday.
Health Secretary Wes Streeting has since written to the British Medical Association saying he is willing to meet the union's resident doctors committee to resume talks.
However, he warned resident doctors have squandered the 'considerable goodwill' they had with Government after the strike.
On Thursday, a Cabinet minister urged health staff to work with the Government on 'delivering the NHS they want to see and we want to see'.
Speaking to reporters in Swindon, Business Secretary Jonathan Reynolds said: 'We know the workforce of the NHS had a difficult decade-and-a-half. We know how they feel.
'But we ask them to work with us on delivering the NHS they want to see and we want to see. We've got to be partners with each other.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

When Medicine Meets Philosophy: A New SEC Series
When Medicine Meets Philosophy: A New SEC Series

Medscape

time3 hours ago

  • Medscape

When Medicine Meets Philosophy: A New SEC Series

Medicine and Philosophy, a new roundtable series by the Spanish Society of Cardiology (SEC) in collaboration with Madrid's Círculo de Bellas Artes, aims to facilitate discussions between medical, science, and humanities experts. The series, which took place in May and June, was recorded and can be viewed online at the SEC's channel. Organizers and Topics The Hippocratic Chapter of the SEC, along with organizers from the Círculo de Bella Artes, decided on three healthcare topics to explore in the series. The session titles were "The Doctor-Patient Relationship in the Era of Artificial Intelligence," "Who Wants to Live Forever?", and "Is Boredom a Medical Problem? AI in Medicine: Pros and Cons AI's role in medicine was the first session's focus. Panelists discussed how AI saves time by streamlining data interpretation, allowing more time spent with patients. Ironically, the extra time results in the expectation that patient load should increase. The importance of physician input in AI advancement for medical use, as well as educating future clinicians on AI, were discussed. A Long Life The concept of living a longer life was discussed in the second session. A balanced approach to the topic by medical professionals and philosophers created a crossover of biological facts with existential questions about the meaning of life. Is Boredom Treatable? The last session featured panelists talking about boredom, whether it is a medical issue, and the social and medical repercussions of labeling these normal emotional life experiences as treatable conditions. Were These Roundtables Successful? Yes. All sessions sold out and this success has prompted the organizers to brainstorm future topics for collaboration. Also, expanding this series outside of Madrid is a possibility. Bottom line: Viewing healthcare topics through scientific and philosophical lenses can foster thought-provoking discussions, as shown by the success of the Medicine and Philosophy roundtable series. The full list of panelists can be found on the Círculo de Bellas Artes page for the roundtable series.

Novo Nordisk shares dip further as Wegovy gains nearly erased
Novo Nordisk shares dip further as Wegovy gains nearly erased

Yahoo

time4 hours ago

  • Yahoo

Novo Nordisk shares dip further as Wegovy gains nearly erased

By Jacob Gronholt-Pedersen (Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent losses that threaten to wipe out all the gains since the drugmaker launched its blockbuster weight-loss treatment Wegovy four years ago. The fall on Friday means the Danish firm has dropped out of the top 10 constituents of the Europe-wide STOXX 600 index. Share price declines across the sector were prompted by U.S. President Donald Trump, who sent letters on Thursday to 17 major pharmaceutical firms, including Novo Nordisk, telling them to cut drug prices in the United States. Novo Nordisk on Tuesday slashed its forecast for 2025 sales growth due to competition from compounded, or copycat, versions of Wegovy and appointed veteran insider Maziar Mike Doustdar as its new CEO, prompting its shares to fall 23% on the day. Novo became Europe's most valuable listed firm after launching Wegovy in June 2021, worth some $650 billion in the middle of last year. But its shares have lost more than two-thirds since on concerns the drugmaker is losing ground in the obesity drug race. Its market cap is now $214.5 billion. "The U.S. healthcare system is complex, but Novo Nordisk will continue to work to find solutions that help people access the medicines they need at affordable prices," Novo said in an emailed statement. Novo's shares were around 2% lower at 1453 GMT, bringing this week's losses to around 30% - the stock's worst week ever. The European healthcare index was down around 1% to its lowest since April. "Trump doesn't have the mandate to tell Novo Nordisk how to price their products in the U.S., but investors are just panicking about the risk of another downgrade," said Nordnet analyst Per Hansen. The pressure to lower prices adds to Novo's problems in the United States, its biggest market. It faces competition from Eli Lilly and from compounders - custom-made medicines that are based on the same ingredients as branded drugs. "This is a repricing of the obesity market, it's a repricing of the United States as the world's most attractive drug market, and it's a repricing of the risk from Donald Trump," Hansen said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Why Moderna (MRNA) Stock Is Trading Lower Today
Why Moderna (MRNA) Stock Is Trading Lower Today

Yahoo

time5 hours ago

  • Yahoo

Why Moderna (MRNA) Stock Is Trading Lower Today

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 7.1% in the afternoon session after the company trimmed the upper end of its 2025 revenue forecast, citing a delay in vaccine shipments. The company pointed to a delay in vaccine deliveries to the United Kingdom, which it pushed into the first quarter of 2026. This news overshadowed second-quarter results that beat Wall Street expectations. For the quarter, Moderna's revenue dropped about 41% from the previous year to $142 million, driven by lower sales of its COVID-19 vaccine. Despite the revenue decline, the company successfully narrowed its net loss as its cost-cutting measures took effect. Adding to the pressure, Moderna also announced plans to reduce its workforce by 10% and confirmed a delay in the U.S. approval for its combined COVID-flu vaccine until 2026. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Moderna? Access our full analysis report here, it's free. What Is The Market Telling Us Moderna's shares are extremely volatile and have had 53 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 3 days ago when the stock dropped 4.9% on the news that industry bellwether UnitedHealth Group (UNH) slashed its 2025 profit forecast after reporting a significant surge in medical costs, sending shockwaves across the health insurance sector. The core of the issue stems from an 'unprecedented medical cost trend environment,' particularly within the Medicare Advantage market, which are privately run versions of the federal health insurance program. UnitedHealth, the largest provider in this space, now expects these costs to rise by 7.5% in 2025, a significant jump from its earlier 5% projection, with the potential to accelerate to almost 10% in 2026. In response, the insurer announced it will drop plans covering over 600,000 people. The company's lowered earnings forecast has raised investor concerns that these surging costs and utilization rates are an industry-wide problem, impacting the profitability of other carriers as well. Moderna is down 34.6% since the beginning of the year, and at $27.47 per share, it is trading 70.8% below its 52-week high of $94.17 from July 2024. Investors who bought $1,000 worth of Moderna's shares 5 years ago would now be looking at an investment worth $352.27. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. 登入存取你的投資組合

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store